E-Cigarette study for schizophrenia smokers pulled before it began
NCT ID NCT01979796
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to test whether electronic cigarettes could help people with schizophrenia quit or reduce smoking. It planned to enroll smokers with schizophrenia from Sicily and compare e-cigarettes with nicotine, without nicotine, and a nicotine-free inhaler. However, the trial was withdrawn before any participants were enrolled, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Electronic cigarette (e-cigarette) with or without nicotine
- What this could lead to
- If it had been completed, this study could have pointed toward a safer way for people with schizophrenia to quit or reduce smoking.
- What could go wrong
- The trial was withdrawn before any participants were enrolled, so no results are available. Even if it had run, the small size and early stage would have limited the strength of any conclusions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Expected to start
-
Dec 2022
An estimate. Start dates often move.
- Expected to finish
-
Dec 2024
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Schizophrenic subjects (according to DSM-IV-TR criteria) from throughout Sicily, (Italy), who smoke tobacco cigarettes, in stable phase of illness. * smoke ≥10 factory made cig/day, for at least the past five years * age 18-65 years * in good general health * not currently attempting to quit smoking or wishing to do so in the next 30 days (a specific test will be included to check their unwillingness to quit) 6 months * committed to follow the trial procedures. Exclusion Criteria: * use of smokeless tobacco or nicotine replacement therapy * pregnancy or breastfeeding. * current or recent (less than 1 yr) past history of alcohol and/or drug abuse * other significant co-morbidities according to the Investigator's clinical assessment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Schizophrenia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug
- A shot every few weeks? new drug tested for schizophrenia